BRCA1 and breast carcinoma: With the approval of poly (ADP-ribose) polymerase inhibitors (PARPi)12–16 for patients with pathogenic germline variants in BRCA1 and BRCA2, the NCCN recommended universal BRCA1/2 germline testing for patients with advanced ovarian and breast cancer as well as expanded homologous recombination repair (HRR) gene testing for prostate cancer17–19.